<div id="readability-page-1"><div id="articlecontent"> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/bicycle-therapeutics-plc-logo-1200x675.png/query-dj0yMDIyMTIwNjExMjYwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/bicycle-therapeutics-plc-logo-1200x675.png/query-dj0yMDIyMTIwNjExMjYwNQ"/>Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) fell 5.8% on Friday . The company traded as low as $23.00 and last traded at $23.08. 469,718 shares traded hands during mid-day trading, an increase of 23% from the average session volume of 381,422 shares. The stock had previously closed at $24.49.</p><div><p><span></span><span>Get <strong>Bicycle Therapeutics</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><p>A number of research firms have recently weighed in on BCYC. Canaccord Genuity Group reaffirmed a &#34;buy&#34; rating and issued a $60.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 21st. HC Wainwright dropped their price objective on Bicycle Therapeutics from $57.00 to $55.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, February 21st. Finally, Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $43.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $47.88.</p><p><b>View Our Latest Research Report on Bicycle Therapeutics</b></p><h2>Bicycle Therapeutics Stock Performance</h2><p>The company has a debt-to-equity ratio of 0.08, a current ratio of 8.08 and a quick ratio of 8.08. The business has a 50-day simple moving average of $23.68 and a 200-day simple moving average of $19.27. The firm has a market capitalization of $693.32 million, a PE ratio of -4.76 and a beta of 0.89. </p><div><div><p><span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDc2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDc2"/></span></p><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2054push_GLD_03.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="158" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2054push_GLD_03.jpg"/></p></div><div><p><b>Ad </b> Stansberry Research</p><p>Strange new buyer driving up gold</p><p>One Wall Street trader just made a big new gold prediction: &#34;Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented.&#34;</p><p>But there's a much better move you can make to get in front of these big moves today.</p></div></div></div><p>Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 20th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.23) by $0.07. Bicycle Therapeutics had a negative return on equity of 57.80% and a negative net margin of 669.72%. The business had revenue of $5.33 million for the quarter, compared to the consensus estimate of $11.68 million. Equities research analysts expect that Bicycle Therapeutics plc will post -5.2 earnings per share for the current fiscal year. </p><h2>Insider Transactions at Bicycle Therapeutics</h2><p>In other news, CEO Kevin Lee sold 3,158 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $23.81, for a total value of $75,191.98. Following the sale, the chief executive officer now directly owns 387,270 shares in the company, valued at $9,220,898.70. The sale was disclosed in a document filed with the SEC, which is available at this link. Over the last three months, insiders have sold 5,312 shares of company stock worth $126,139. 10.20% of the stock is currently owned by company insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of BCYC. JPMorgan Chase &amp; Co. grew its stake in Bicycle Therapeutics by 250.2% in the first quarter. JPMorgan Chase &amp; Co. now owns 9,903 shares of the company's stock worth $434,000 after purchasing an additional 7,075 shares in the last quarter. Loomis Sayles &amp; Co. L P boosted its position in Bicycle Therapeutics by 12.9% during the 1st quarter. Loomis Sayles &amp; Co. L P now owns 643,775 shares of the company's stock valued at $28,249,000 after acquiring an additional 73,728 shares in the last quarter. UBS Group AG boosted its position in Bicycle Therapeutics by 896.0% during the 1st quarter. UBS Group AG now owns 8,884 shares of the company's stock valued at $389,000 after acquiring an additional 7,992 shares in the last quarter. Vident Investment Advisory LLC boosted its position in Bicycle Therapeutics by 20.3% during the 1st quarter. Vident Investment Advisory LLC now owns 21,572 shares of the company's stock valued at $947,000 after acquiring an additional 3,639 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new stake in Bicycle Therapeutics during the 1st quarter valued at $341,000. Institutional investors own 86.15% of the company's stock. </p><h2>Bicycle Therapeutics Company Profile</h2><p> (Get Free Report)</p><p>Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Bicycle Therapeutics</li><li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li><li>Comprehensive Analysis of PayPal Stock</li><li>The 3 Best Fintech Stocks to Buy Now</li><li>Intuitive Surgical Stock Can Trend Much Higher This Year </li><li>What is a Low P/E Ratio and What Does it Tell Investors?</li><li>Alibaba Stock Analysis: Insights, Trends, and Future Predictions</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Strange new buyer driving up gold <span><span><span>(From Stansberry Research)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDc2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDc2"/></span></p><h2>Should you invest $1,000 in Bicycle Therapeutics right now?</h2><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p><p>While Bicycle Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here </p><div><div><div><p><img height="209" width="170" src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/premium-reports/small_20231017095516_reportpreview2023-10-ten-best-stocks-2024-cover.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/premium-reports/small_20231017095516_reportpreview2023-10-ten-best-stocks-2024-cover.png"/></p></div><div><div><p>10 Best Stocks to Own in 2024</p><p>Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. </p><p>Get This Free Report</p></div></div></div></div> </div></div>

BCYC

NDAQ

<p>Bicycle Therapeutics (NASDAQ: BCYC) shares fell 5.8% on Friday, trading as low as $23.00. Analysts have set a consensus target price of $47.88. The company reported better-than-expected earnings per share for the quarter. Insiders have sold shares, while hedge funds and institutional investors have bought and sold shares. Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for underserved diseases.</p>

Bicycle Therapeutics (NASDAQ:BCYC) Shares Down 5.8%